DARA II: si ricomincia da qui
- Creatore Discussione ewilly1
- Data di inizio
DARA BioSciences Announces Breast Cancer CAPTURE Registry Abstract Accepted for Poster Presentation at National Comprehensive Cancer Network(R) (NCCN(R)) 19th Annual Conference: Advancing the Standard of Cancer Care(TM)
CAPTURE: Compliance and Preference for Tamoxifen Registry Findings Provide Important New Insights Concerning Tamoxifen Adherence Based Upon Stated Patient Experience and Preference
Marketwired
13 minutes ago
RALEIGH, NC--(Marketwired - February 10, 2014) - DARA BioSciences, Inc. (DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced that the Company's abstract entitled "CAPTURE (Compliance and Preference for Tamoxifen Registry) patient survey reveals potential strategies to improve long-term adherence to TAM based on choice: results of a large internet-based survey" has been accepted for poster presentation at the upcoming National Comprehensive Cancer Network®(NCCN®) 19th Annual Conference: Advancing the Standard of Cancer Care™ -- March 13 - 15, 2014 in Hollywood, FL.
The abstract has been selected for poster presentation during General Poster Session One on March 13, 2014. The lead author, Stefan Glück MD, PhD, FRCPC, Sylvester Distinguished Professor, Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center in the University of Miami's Miller School of Medicine and within the University of Miami Health System (UHealth) and a member of the CAPTURE Scientific Steering Committee, will present the poster.
Additionally, DARA's abstract is expected to be published in an upcoming issue of JNCCN - Journal of the National Comprehensive Cancer Network, a peer-reviewed indexed medical journal that reaches more than 22,000 oncologists and other cancer care professionals across the United States. NCCN, a not-for-profit alliance of 23 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
"We are very pleased to have our CAPTURE abstract accepted by this prominent, oncology-focused organization," commented David J. Drutz M.D., DARA's CEO and Chief Medical Officer. "Our goal for initiating CAPTURE was to generate important, patient-centric information regarding demographics and medication compliance of breast cancer patients taking tamoxifen tablets, including their expressed potential preference for a liquid formulation. We look forward to reporting the data from this study and believe the key findings will raise awareness of opportunities to help improve long-term compliance with this life-saving therapy."
CAPTURE was initiated in 2013, subsequent to DARA's commercialization of Soltamox®(tamoxifen citrate) oral solution, the only FDA-approved liquid formulation of tamoxifen citrate in the United States. A total of 626 women from 17 nationwide oncology practices who had been prescribed and were taking tamoxifen therapy for breast cancer completed the CAPTURE survey, providing investigators with valuable insight into adherence to prescribed tamoxifen tablets based on patient preference for a liquid formulation of tamoxifen or patient prevalence of swallowing difficulties.
Tamoxifen is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, the reduction of risk of invasive breast cancer in women with ductal carcinoma in situ, and to reduce breast cancer incidence in high risk women. Currently, more than 1.7 million prescriptions of tamoxifen are written annually in the United States. Between 31 and 61 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer and breast cancer recurrence.
The NCCN Annual Conference: Advancing the Standard of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas. The NCCN Annual Conference also includes case study discussion forums with experts from NCCN Member Institutions and roundtable discussions featuring the foremost professionals from the academic, patient advocacy, government, payer, industry, and business realms of cancer care.
CAPTURE: Compliance and Preference for Tamoxifen Registry Findings Provide Important New Insights Concerning Tamoxifen Adherence Based Upon Stated Patient Experience and Preference
Marketwired
13 minutes ago
RALEIGH, NC--(Marketwired - February 10, 2014) - DARA BioSciences, Inc. (DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced that the Company's abstract entitled "CAPTURE (Compliance and Preference for Tamoxifen Registry) patient survey reveals potential strategies to improve long-term adherence to TAM based on choice: results of a large internet-based survey" has been accepted for poster presentation at the upcoming National Comprehensive Cancer Network®(NCCN®) 19th Annual Conference: Advancing the Standard of Cancer Care™ -- March 13 - 15, 2014 in Hollywood, FL.
The abstract has been selected for poster presentation during General Poster Session One on March 13, 2014. The lead author, Stefan Glück MD, PhD, FRCPC, Sylvester Distinguished Professor, Department of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center in the University of Miami's Miller School of Medicine and within the University of Miami Health System (UHealth) and a member of the CAPTURE Scientific Steering Committee, will present the poster.
Additionally, DARA's abstract is expected to be published in an upcoming issue of JNCCN - Journal of the National Comprehensive Cancer Network, a peer-reviewed indexed medical journal that reaches more than 22,000 oncologists and other cancer care professionals across the United States. NCCN, a not-for-profit alliance of 23 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
"We are very pleased to have our CAPTURE abstract accepted by this prominent, oncology-focused organization," commented David J. Drutz M.D., DARA's CEO and Chief Medical Officer. "Our goal for initiating CAPTURE was to generate important, patient-centric information regarding demographics and medication compliance of breast cancer patients taking tamoxifen tablets, including their expressed potential preference for a liquid formulation. We look forward to reporting the data from this study and believe the key findings will raise awareness of opportunities to help improve long-term compliance with this life-saving therapy."
CAPTURE was initiated in 2013, subsequent to DARA's commercialization of Soltamox®(tamoxifen citrate) oral solution, the only FDA-approved liquid formulation of tamoxifen citrate in the United States. A total of 626 women from 17 nationwide oncology practices who had been prescribed and were taking tamoxifen therapy for breast cancer completed the CAPTURE survey, providing investigators with valuable insight into adherence to prescribed tamoxifen tablets based on patient preference for a liquid formulation of tamoxifen or patient prevalence of swallowing difficulties.
Tamoxifen is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, the reduction of risk of invasive breast cancer in women with ductal carcinoma in situ, and to reduce breast cancer incidence in high risk women. Currently, more than 1.7 million prescriptions of tamoxifen are written annually in the United States. Between 31 and 61 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer and breast cancer recurrence.
The NCCN Annual Conference: Advancing the Standard of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas. The NCCN Annual Conference also includes case study discussion forums with experts from NCCN Member Institutions and roundtable discussions featuring the foremost professionals from the academic, patient advocacy, government, payer, industry, and business realms of cancer care.
DARA - $.52 - ZACK's Buy Rating - Update 2/6/14
Highlights below from the PDF...
February 6, 2014
Jason Napodano, CFA
jnapodano@zacks.com
PDF Link: http://scr.zacks.com/files/doc_cove...podano/DARA/February 6 2014_DARA_Napodano.pdf
ODD Status: …No Update On KRN5500 ODD…
DARA’s Form 10K filed on February 4, 2014 provided little update on the status of the pending Orphan Drug Designation (ODD) decision from the U.S. FDA on KRN5500. The language from the annual report (posted below) is similar to the last update from the company in November 2013:
------------------------------
We had a brief conversation with the company for the preparation of this report. Management told us they remain in “active dialogue” with the U.S. FDA on the ODD application. This is important because many investors have asked us if the application has been rejected or moved to the back burner at either the agency of the company. This does not seem to be the case. We are hoping for a decision in the next few months.
--------------------------------
We believe DARA’s stock remains attractively valued. Revenues in 2012 were non-existent. In 2013, revenues totaled only $0.42 million, again…pretty low.
However, based on the recent sales force expansion and the three new products DARA is now co-promoting from Mission Pharmacal, we think DARA can do over $2.0 million in revenues in 2014 and $10+ million in revenues in 2016. If our modeling holds, the stock should be trading at over $5.00 by year-end 2014 (post-split), and that is based solely on the six current marketed products and has no value for KRN5500. We think orphan drug designation on KRN5500 could triple the market value of the company. A licensing partner will probably be announced soon after the FDA’s decision. Our conclusion is that investors can buy DARA now and get both an emerging specialty pharmaceutical story at a reasonable price, and a Phase 2b drug in KRN5500 for free.
Current Recommendation Buy
Prior Recommendation Neutral
Date of Last Change 09/13/2012
Current Price (02/06/14) $0.52
Target Price $1.50
Highlights below from the PDF...
February 6, 2014
Jason Napodano, CFA
jnapodano@zacks.com
PDF Link: http://scr.zacks.com/files/doc_cove...podano/DARA/February 6 2014_DARA_Napodano.pdf
ODD Status: …No Update On KRN5500 ODD…
DARA’s Form 10K filed on February 4, 2014 provided little update on the status of the pending Orphan Drug Designation (ODD) decision from the U.S. FDA on KRN5500. The language from the annual report (posted below) is similar to the last update from the company in November 2013:
------------------------------
We had a brief conversation with the company for the preparation of this report. Management told us they remain in “active dialogue” with the U.S. FDA on the ODD application. This is important because many investors have asked us if the application has been rejected or moved to the back burner at either the agency of the company. This does not seem to be the case. We are hoping for a decision in the next few months.
--------------------------------
We believe DARA’s stock remains attractively valued. Revenues in 2012 were non-existent. In 2013, revenues totaled only $0.42 million, again…pretty low.
However, based on the recent sales force expansion and the three new products DARA is now co-promoting from Mission Pharmacal, we think DARA can do over $2.0 million in revenues in 2014 and $10+ million in revenues in 2016. If our modeling holds, the stock should be trading at over $5.00 by year-end 2014 (post-split), and that is based solely on the six current marketed products and has no value for KRN5500. We think orphan drug designation on KRN5500 could triple the market value of the company. A licensing partner will probably be announced soon after the FDA’s decision. Our conclusion is that investors can buy DARA now and get both an emerging specialty pharmaceutical story at a reasonable price, and a Phase 2b drug in KRN5500 for free.
Current Recommendation Buy
Prior Recommendation Neutral
Date of Last Change 09/13/2012
Current Price (02/06/14) $0.52
Target Price $1.50
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
Io apro short almeno fino a 1,2
ewilly1
Nuovo Utente
- Registrato
- 25/2/08
- Messaggi
- 2.527
- Punti reazioni
- 42
Complimenti... Una previsione simil falco
Miki & Varenne
Nuovo Utente
- Registrato
- 18/6/09
- Messaggi
- 48.694
- Punti reazioni
- 332
beh solo che le mie previsioni al 99% le ho sempre centrate
a diferenza di poiana, perche tu credi che dara non ci arriva a li?
ewilly1
Nuovo Utente
- Registrato
- 25/2/08
- Messaggi
- 2.527
- Punti reazioni
- 42
Perché sono entrati investitori che qualcosa vorranno guadagnarci, il flottante e' modesto e credo sia più probabile un rialzo su news, in particolare se esce quella sulla orphan drug, e' già stata abbastanza bastonata
Ultima modifica:
l'unica è l'ODD
DARA's Form 10K filed on February 4, 2014 provided little update on the status of the pending Orphan Drug Designation (ODD) decision from the U.S. FDA on KRN5500. The language from the annual report (posted below) is similar to the last update from the company in November 2013:
We had a brief conversation with the company for the preparation of this report. Management told us they remain in "active dialogue" with the U.S. FDA on the ODD application. This is important because many investors have asked us if the application has been rejected or moved to the back burner at either the agency of the company. This does not seem to be the case. We are hoping for a decision in the next few months.
ODD on KRN5500 Still Pending
DARA's Form 10K filed on February 4, 2014 provided little update on the status of the pending Orphan Drug Designation (ODD) decision from the U.S. FDA on KRN5500. The language from the annual report (posted below) is similar to the last update from the company in November 2013:
We had a brief conversation with the company for the preparation of this report. Management told us they remain in "active dialogue" with the U.S. FDA on the ODD application. This is important because many investors have asked us if the application has been rejected or moved to the back burner at either the agency of the company. This does not seem to be the case. We are hoping for a decision in the next few months.
Dara BioSciences raises $6M in a registered direct offering
18 minutes ago
Dara BioSciences entered into a securities purchase agreement with certain institutional investors providing for the issuance and sale by the Company in a registered direct offering of 2,166,501 shares of the Company's common stock at an offering price of $2.765 per share for gross proceeds of approximately $6M.
=================
ADC sottoscritto ad un prezzo maggiore all'attuale senza CW e pippe varie
vediamo cosa bolle in pentola e se da qui magari si riparte senza test dei minimi
Con maggiore dettaglio:
=================
8:31 am DARA BioSciences enters into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the co in a registered direct offering of 2,166,501 shares of the co's common stock at $2.765 per share (DARA) :
Co announced that on February 11, 2014, DARA BioSciences entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the Company in a registered direct offering of ~2.166 mln shares of the Company's common stock, par value $0.01 per share, at an offering price of $2.765 per share for gross proceeds of ~$6.0 million before deducting for placement agent fees and expenses.
The Shares are being offered by the Company pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission on March 25, 2011 and declared effective on April 19, 2011.
The Company estimates that the net proceeds from the Offerings will be ~$5.5 mln. The net proceeds received by the Company from the Offerings will be used for working capital and general corporate purposes, which may include funding commercial activities related to the Company's product portfolio and the Mission Pharmacal products including in connection with the Company's agreements with Mission and Alamo.
18 minutes ago
Dara BioSciences entered into a securities purchase agreement with certain institutional investors providing for the issuance and sale by the Company in a registered direct offering of 2,166,501 shares of the Company's common stock at an offering price of $2.765 per share for gross proceeds of approximately $6M.
=================
ADC sottoscritto ad un prezzo maggiore all'attuale senza CW e pippe varie
vediamo cosa bolle in pentola e se da qui magari si riparte senza test dei minimi
Con maggiore dettaglio:
=================
8:31 am DARA BioSciences enters into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the co in a registered direct offering of 2,166,501 shares of the co's common stock at $2.765 per share (DARA) :
Co announced that on February 11, 2014, DARA BioSciences entered into a Securities Purchase Agreement with certain institutional investors providing for the issuance and sale by the Company in a registered direct offering of ~2.166 mln shares of the Company's common stock, par value $0.01 per share, at an offering price of $2.765 per share for gross proceeds of ~$6.0 million before deducting for placement agent fees and expenses.
The Shares are being offered by the Company pursuant to an effective shelf registration statement on Form S-3, which was initially filed with the Securities and Exchange Commission on March 25, 2011 and declared effective on April 19, 2011.
The Company estimates that the net proceeds from the Offerings will be ~$5.5 mln. The net proceeds received by the Company from the Offerings will be used for working capital and general corporate purposes, which may include funding commercial activities related to the Company's product portfolio and the Mission Pharmacal products including in connection with the Company's agreements with Mission and Alamo.
amedeo8
Corsi / Ricorsi
- Registrato
- 13/1/09
- Messaggi
- 16.465
- Punti reazioni
- 263
Ultima modifica:
viper69
Nuovo Utente
- Registrato
- 17/1/14
- Messaggi
- 1.295
- Punti reazioni
- 28
dici? cosa te lo fa pensare? il fatto che non daranno la stato orphan drug ?
davide.toc
Nuovo Utente
- Registrato
- 3/11/13
- Messaggi
- 10
- Punti reazioni
- 0
ciao, qualche settimana fa seguivo questo titolo con un valore intorno ai 0,5 0,6... come mai guardano i grafici non risultano questi valori?
grazie
grazie
